Pancreatic Cancer Research

Clinical trialEarly Phase 1Withdrawn

A Phase 1 Study to Evaluate Paclitaxel Conjugated CXC Receptor 4 Antagonist (MB1707) in Patients With Advanced Cancer

A Phase 1 Study to Evaluate the Pharmacokinetics and Safety of MB1707 in Patients With Advanced Cancer

Outcome
Stopped earlyThe study was terminated due to Sponsor decision (Business decision)
Phase
Early Phase 1
Status
Withdrawn
Study type
Interventional
Planned start
December 2022
Planned end
December 2024
Enrollment
0 participants
Sites
0
Primary outcomes
Incidence of Adverse Events (AE) as characterized by type, frequency, severity (NCI CTCAE Version 5.0), timing, seriousness, and relationship to study therapy; Peak Plasma Concentration (Cmax); Time to Cmax (Tmax); Area under the concentration-time curve from time 0 to the last quantifiable concentration (AUC0-t); Area under the concentration-time curve extrapolated to infinity (AUC∞)
Sponsor type
Industry
Results posted
No
Last update
21 December 2023

These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.

Ask this document

Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.

Try

Source text

Brief summary public domain (ClinicalTrials.gov)

The study will evaluate the pharmacokinetics (PK) and safety of a single intravenous (IV) dose of 0.3 mg/kg MB1707 in patients with advanced cancers.

Detailed description public domain (ClinicalTrials.gov)

MB1707, paclitaxel (PTX) conjugated CXC chemokine receptor 4 (CXCR4) peptide antagonist, a peptide-drug conjugate (PDC), for the treatment of cancer. MB1707 is a potent CXCR4 antagonist which inhibits tumor growth and metastasis by blocking the stromal cell derived factor 1 (SDF-1, a.k.a. CXCL12)/CXCR4 signaling pathway. MB1707 contains a conjugated drug, paclitaxel. By specific binding to CXCR4 overexpressed by the tumor cells, MB1707 has a built-in targeted delivery mechanism. The study will evaluate the PK and safety of a single intravenous (IV) dose of 0.3 mg/kg MB1707 in patients with advanced cancers. Up to 6 patients will be enrolled. Patients will be treated with a single intravenous (IV) dose of MB1707 over 3 hours on Day 1 only. Patients will be pre-medicated with an antihistamine (eg, diphenhydramine), a corticosteroid (e.g., dexamethasone), and a H2 receptor antagonist (e.g., famotidine), within 30 to 60 minutes prior to infusion at doses per institutional guidelines. Patients will be observed for 60 minutes after Cycle 1 dose administration. Patients will complete a 14-day Safety Follow-up Visit following the single dose.